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Abstract: Genome editing technologies have led to fundamental changes in genetic science. Among them, CRISPR-Cas9 technology
particularly stands out due to its advantages such as easy handling, high accuracy, and low cost. It has made a quick introduction in
fields related to humans, animals, and the environment, while raising difficult questions, applications, concerns, and bioethical issues
to be discussed. Most concerns stem from the use of CRISPR-Cas9 to genetically alter human germline cells and embryos (called
germline genome editing). Germline genome editing leads to serial bioethical issues, such as the occurrence of undesirable changes
in the genome, from whom and how informed consent is obtained, and the breeding of the human species (eugenics). However, the
bioethical issues that CRISPR-Cas9 technology could cause in the environment, agriculture and livestock should also not be forgotten.
In order for CRISPR-Cas9 to be used safely in all areas and to solve potential issues, worldwide legislation should be prepared, taking
into account the opinions of both life and social scientists, policy makers, and all other stakeholders of the sectors, and CRISPR-Cas9
applications should be implemented according to such legislations. However, these controls should not restrict scientific freedom. Here,
various applications of CRISPR-Cas9 technology, especially in medicine and agriculture, are described and ethical issues related to
genome editing using CRISPR-Cas9 technology are discussed. The social and bioethical concerns in relation to human beings, other
organisms, and the environment are addressed.
Key words: Genome editing, CRISPR-Cas9 technology, bioethical issues, bioethics

1. Introduction
For many years, molecular biologists have sought ways
to use cellular repair mechanisms to manipulate DNA
through genome editing. In this way, they would have the
power to change the genome by correcting a mutation or
introducing a new function (Rodriguez, 2016). For this
purpose, genome editing technologies were developed
(Memi et al., 2018). In recent years, clustered regularly
interspaced short palindromic repeats technology
(CRISPR-Cas9) has become the most preferred method of
gene editing. This technology has advantages such as high
accuracy, easy handling, and relatively low cost compared to
previous technologies, such as zinc-finger nuclease (ZFN)
and transcription activator-like effector nuclease (TALEN).
Thanks to these benefits, CRISPR-Cas9 technology can be
easily applied in any molecular biology laboratory.
Genome editing technologies are used in the formation
of human disease models in experimental animals and for
the understanding of basic gene functions. They also have
great therapeutic potential for future treatment of untreated
diseases such as certain cancers, genetic disorders, and

HIV/AIDS. Today, genome editing in somatic cells is one
of the promising areas of therapeutic development (Otieno,
2015). However, various bioethical issues have arisen due
to the potential impact of these technologies on the safety
of food stocks and clinical applications (Hundleby and
Harwood, 2018; Hirch et al., 2019). This review discusses
the challenges, possible consequences, and bioethical
issues of CRISPR-Cas9 in detail.
2. Biology and function of CRISPR-Cas9 technology
Genome editing technologies often work by creating
fractures in chromosomal DNA. ZFN, TALEN, and
CRISPR-Cas9 are all based solely on nucleases (Kim
and Kim, 2014; Roh et al., 2018). The strength of these
technologies stems from the ability to create fractures in the
desired region of a specific target sequence as determined
by the researcher. This allows researchers to modify the
genome in practice in any region (Memi et al., 2018).
The creation of changes in the genome depends mainly
on the DNA repair capacity of the cells (Lau et al., 2018).
All cells have two basic mechanisms for the repair of double
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chain breaks on DNA. One of them is nonhomologous
end joining (NHEJ) and the other is the homologous
dependent repair (HDR) mechanism. In NHEJ, the ends of
the fractures are quickly connected directly to each other,
regardless of the sequence homology, while HDR requires
homology to repair the damaged DNA site. In order to
achieve homology, the undamaged sister chromatid is
used as a template and DNA damage is repaired (Urnov,
2018).
CRISPR-Cas9 is a naturally occurring defense system in
prokaryotic organisms that provides resistance to foreign
genetic elements such as plasmids and bacteriophages
(Barrangau et al., 2007; Marraffini and Sontheimer, 2008).
When the virus or plasmid enters a bacterial cell, CRISPRCas9 allows the addition of short viral DNA molecules
to the CRISPR site. CRISPR sequences (CRISPRs) are
short DNA repeats of viral or plasmid origin found in the
genomes of bacteria and are defined as clustered regularly
interspaced short palindromic repeats. Cas genes (CRISPRrelated) are genes that encode nuclease or helicase proteins
associated with CRISPR repeat sequences that have the
function of cutting or dissolving DNA (Jansen et al., 2002).
Cas9, a member of the Cas gene family, was isolated from
Streptococcus pyogenes and is an endonuclease capable of
cutting DNA from two active cut regions at both ends of
the DNA double helix (Doudna and Charpentier, 2014;
Rodriguez, 2016). The CRISPR-Cas system recognizes the
DNA of the invading virus or bacterium and directs the
Cas protein to destroy foreign DNA (Otieno, 2015).
In the following years, it was discovered that the
CRISPR-Cas system can be programmed to find and cut
specific target DNA regions, thereby providing genome
editing (Jinek et al., 2012; Hsu et al., 2013). As a result of
understanding that the human genome can be edited by
CRISPR-Cas9, it became clear that genome editing could
also be used for therapeutic purposes, and a new era in
genetic engineering began (Lau et al., 2018; Roh et al.,
2018).
3. Application areas
3.1. Animal models
CRISPR-Cas9 can be used to create animal models
to mimic human diseases and to understand disease
development by mutating or silencing genes. A mouse
model has been developed to determine the harmful
effects of mutations in cancer by making mutations that
cause the loss of function in tumor suppressor genes or
give functions to protooncogenes (Chin, 2015).
Conventional genetically modified (GM) mouse
models are produced by gene targeting in embryonic
stem cells or transgenesis, which are time-consuming
and highly expensive. With CRISPR-Cas9, GM mice can
be efficiently produced in a much shorter time (Mei et

al., 2016). It can be applied to nonhuman primates such
as monkeys. Nonhuman primates are more similar to
humans in anatomical, physiological, and genetic terms
than rodents (Zhang et al., 2014). Therefore, they are more
suitable models than rodents in understanding human
biology and disease development (Xin et al., 2016). The
first successful application of CRISPR-Cas9 in nonhuman
primates, from which a knockout monkey was produced,
was realized in 2014 (Niu et al., 2014). However, genome
sequences of many nonhuman primates are not yet fully
identified. This makes it difficult to design selected singleguide RNAs (sgRNAs) (Gou and Li, 2015; Lou et al., 2016).
Therefore, the application of CRISPR-Cas9 in nonhuman
primates is still at an early stage.
3.2. Genome editing in specific tissues
Researchers have been able to modify the genomes of
specific tissues such as liver and brain tissues using
hydrodynamic injection and adeno-associated virus
(AAV) (Rodriguez et al., 2014; Senis et al., 2014). In a
study, CRISPR-Cas9 has been successfully and effectively
applied to the mammalian nervous system. A mixture
of green fluorescent protein (GFP)-labeled AAV-spCas9
and AAV-spGuide plasmids was transferred in vivo to
the hippocampal toothed brain folds of adult male mice
(Swiech et al., 2015). It is thought that the number of
such applications will grow in the fields of cancer and
neuroscience in the following years (Mei et al., 2016).
3.3. Multiple gene mutations
CRISPR-Cas9 can be used to generate mutants for target
genes. In the first such study by Li et al., six sgRNAs
targeting Cas9 mRNA and six different genomic regions
encoding the Tet1, Tet2, and Tet3 genes were transferred
to the cytoplasm of rat embryos (Li et al., 2013). Findings
showed that all three Tet genes carried the desired
mutations in 59% of newborn rat pups. Successful results
were also reported in studies with zebrafish embryos and
Arabidopsis as well (Ota et al., 2014; Wang et al., 2015).
3.4. Epigenome studies
Epigenome studies can be performed in two different ways:
genome or epigenome editing (Chen et al., 2014; Huisman
et al., 2015). In genome editing, nuclease is used to modify
the DNA sequence, whereas in epigenome editing, an
effector domain is used and the DNA sequence is not
changed. This function is achieved by catalytic inactivation
of the Cas9-associated effector domain by replacing
the Cas9 protein. Altered effector proteins are used to
activate or suppress transcription (Lau and Davie, 2016).
In epigenome editing, the epigenome can be modified
by changing the proteins that maintain and protect the
epigenome. Suppression of DNA methylation as a result
of degradation of catalytic domains that accelerate the loss
of spherical DNA methylation in human cells and lead to
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cell death is a good example of epigenome studies using
CRISPR-Cas9 (Liao et al., 2015).
Another application is the editing of long nonencoded
RNAs (lncRNAs) and enhancer RNAs (eRNAs) that can
control gene expression and epigenome processes. In a
study, eRNA-expression factors and IncRNA-expression
enhancers were suppressed by stimulating deletion
mutations in a lymphoma cell line using CRISPR-Cas9
(Pefanis et al., 2015). It is predicted that CRISPR-Cas9
may allow different levels of epigenome modification and
facilitate further changes to humans (Liao et al., 2015; Mei
et al., 2016).
3.5. Treatment of diseases
CRISPR-Cas9 can be applied to cells in vivo or ex vivo. In
the in vivo approach, CRISPR-Cas9 is directly transferred
to cells in the body using either viral or nonviral methods.
In the ex vivo approach, first the cells are removed from
the body; then CRISPR is applied to the cells and they
are transferred back to the body (Roh et al., 2018). This
approach has great potential to develop tissue-based
therapies (Rath et al., 2015). Using CRISPR-Cas9, the
mutation in the dystrophin protein responsible for the
most common form of Duchenne muscular dystrophy
was successfully removed (Amoasii et al., 2018; Duchêne
et al., 2018; Koo et al., 2018; Long et al., 2018). There are
studies to prevent and treat AIDS by inhibiting the entry
of HIV into the cell or by removing the HIV genome
integrated into the host genome using CRISPR-Cas9
(Saayman et al., 2015). Induced pluripotent stem cells
(iPSCs) were successfully produced from cystic fibrosis
patients with confirmed F508 deletion in the cystic fibrosis
transmembrane regulator (CFTR) gene by CRISPR-Cas9
(Firth et al., 2015). There are also studies for cataracts
(Wu et al., 2015; Yang et al., 2016) and Parkinson’s disease
(Yang et al., 2016). However, recent studies have shown
that CRISPR-Cas9 activates the type 1 interferon (INF)
pathway, causing a type 1 INF-mediated immune response
(Kim et al., 2018; Charleswort et al., 2019). These findings
currently limit the use of CRISPR-Cas9 in treatment.
3.6. Industrial uses
CRISPR was first used for commercial purposes to make
bacterial cultures used in cheese and yogurt production
resistant to viral infections (van Erp et al., 2015). One of
the applications in agriculture is to produce GM crops
(Hundleby and Harwood, 2019). There are attempts to
increase the yield in the livestock industry (van Erp et
al., 2015). It can be used to control invasive pest species
to reverse pesticide and herbicide resistance in insects
and weeds or to prevent disease spread (Esvelt et al.,
2014). Researchers have succeeded in preventing the
spread of genes protecting mosquitoes from harmful
malaria parasites (Gantz et al., 2015) and making female
mosquitoes infertile in the laboratory (Hammond et al.,
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2016). Vaccine development is another significant area
of interest. The smallpox virus vector (VACV) is used
in the eradication and vaccination of smallpox. Using
CRISPR-Cas9, the efficiency of marker-free VACV vectors
has been increased (Yuan et al., 2015). Another example
is the hepatitis B vaccine. In order to prevent viral gene
expression and replication, specific regions of the hepatitis
B genome were targeted and cut by CRISPR-Cas9
(Ramanan et al., 2015).
3.7. RNA editing
Single-stranded RNA (ssRNA) sequences can also be
edited by CRISPR-Cas9. In RNA editing, CRISPR-Cas9
consists of a DNA oligonucleotide presenting the PAM
(protospacer adjacent motif) region (PAMmer), ssRNA,
guide RNA (gRNA), and Cas9 protein. PAMmer acts as
a PAM region specifically recognized by Cas9 and directs
Cas9 to bind and cut the target ssRNA. 5’-Elongated
PAMmers containing bases paired with different ssRNAs
and immediately in front of PAM are required for specific
binding of target ssRNAs. Since RNA molecules have
different functions than DNA, CRISPR-Cas9 can offer a
much more flexible application than other genome editing
methods (Mei et al., 2016).
3.8. Military applications
One of the lesser-discussed application areas of CRISPRCas9 technology is its use for military purposes. As is
known, a substantial portion of genome editing studies
are supported by the defense ministries of the countries.
These studies are commonly focused on increasing
the tolerance of soldiers against biological or chemical
warfare. This technology has the potential to influence
human performance optimization (Greene and Master,
2018). Studies are usually concentrated on discovering
different genes that can be harnessed from other species
(Gracheva et al., 2010) and identifying new genes that can
be associated with posttraumatic stress disorder, which is
frequently experienced by soldiers (Cornelis et al., 2010).
In a study by Zou et al. (2015), researchers developed dog
embryos with higher muscle mass using CRISPR-Cas9.
Another interesting study showed that the CMG2 gene,
known to cause low sensitivity to anthrax toxin when
expressed in small amounts, could be silenced by this
technology (Arévalo et al., 2014). However, it should be
noted that far more research needs to be conducted for
using CRISPR technology in humans as a defense tool
against biological and chemical weapons (Greene and
Master, 2018).
3.9. DNA replacement in human embryos (germline
genome therapy)
The most controversial usage of CRISPR-Cas9 is the
modification of human embryo DNA, or, in other words,
its use for germline genome therapy. In 2015, a group of
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Chinese researchers led by Junjiu Huang applied CRISPRCas9 to remove a mutation that causes β-thalassemia,
which is a fatal blood disease, from the human β-globulin
(HBB) gene in the germline of human embryos. In this
research, six abnormal embryos not suitable for in vitro
fertilization were used. The mutation could be corrected
in only one of the embryos. Although the mutation could
be corrected in two other embryos, nontarget effects
occurred in other genes. In the other three embryos, the
mutation could not be corrected. It has been reported
that this technique is not ready for clinical use because
of nontarget effects on different genes (Roh et al., 2018;
Carroll, 2019). Modifications that occur in germline cells
can be transferred to future generations. Scientists think
that they can extract genes that cause diseases in the
population using CRISPR-Cas9 (Cai et al., 2018; Memi et
al., 2018).
4. Bioethical issues
The fact that CRISPR-Cas9 is among the important
discoveries of the 21st century is widely accepted in the
scientific community and related industries. However,
the rapid rise of CRISPR-Cas9 has led to new bioethical,
social, and legal issues in medicine, agriculture, livestock,
and the environment. Possible risks and bioethical issues
related to CRISPR-Cas9 are summarized in the Table.
4.1. Ecological imbalance
In studies using RNA-targeted gene editing methods based
on CRISPR-Cas9, nontarget effects should be examined in

depth. Since gene drift will persist in a population, possible
off-target mutations will continue in each generation. In
addition, the number and effect of mutations may increase
as generations progress (Rodriguez, 2016; Hundleby
and Harwood, 2019). Another concern is the possibility
that genes can be transferred to other species in the
environment. Transferring the regulated sequences to
other species may result in the transmission of negative
characteristics to the associated organisms (Esvelt et al.,
2014). The distribution of the properties of the entrained
genes among the populations can make control very
difficult.
4.2. Regulations for consumers
The use of CRISPR-Cas9 to obtain the desired genetic
modifications makes it very difficult to identify and regulate
genetically modified organisms (GMOs) in the market after
they leave the laboratory. Therefore, regulatory agencies,
such as the US Food and Drug Administration (FDA),
European Medicines Agency (EMA), and others, should
consider whether any GMOs are suitable for consumers.
However, it is not known exactly how to evaluate the
possibilities of a growing market with CRISPR-Cas9
(Ledford, 2015; Hundleby and Harwood, 2019).
One of the dilemmas of CRISPR-Cas9 that concerns
all the humanity is patenting. As is known, transgenic
organisms of industrial use and also some human gene
sequences for clinical purposes have been patented
(Rodriguez, 2016; Sherkow, 2018). As technologies such
as CRISPR continue to evolve, patent-related issues in

Table. Possible risks and bioethical issues related to CRISPR-Cas9 technology.
Organism

Risks

Bioethical issues

References

Bacteria

Nontarget mutations
Gene drifts

Ecological imbalance

Rodriguez, 2016
Hundleby and Harwood, 2019
Esvelt et al., 2014

Plants

Nontarget mutations
Gene drifts

Ecological imbalance
Patenting

Shinwari et al., 2017
Hundleby and Harwood, 2019

Nontarget mutations

Ecological imbalance
Patenting
Animal welfare and dignity
Threatening of human dignity and identity

Rodriguez, 2016
Polcz and Lewis, 2016
Rodriguez, 2017 Eriksson et al., 2018
Koplin, 2019 Degrazia, 2019
de Graeff et al., 2019

Nontarget mutations
Side effects
Cost
Genetic mosaicism

Eugenics
Informed consent
Enhancement
Accessibility
Patenting
Safety
Incomplete or over legislations

Otieno, 2015
Rodriguez, 2016
Duardo-Sánchez, 2017
Shinwari et al., 2017
Greene and Master, 2018
Sherkow, 2018
Cathomen et al., 2019
Hirsch et al., 2019

Animals /
chimeric animals

Humans
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many areas of biotechnology will continue to increase
in the upcoming years. Even today, there are many such
cases of patenting. The best-known case is the patent right
case between Zhang and Doudna and Charpentier for the
therapeutic use of CRISPR-Cas9 in human cells. In the
case concluded on 2 December 2016, it was decided to
grant the patent to Caribou Biosciences, which Doudna
was the founder of (Donohoue et al., 2018).
4.3. Genome editing for enhancement
The editing of human germline cells with CRISPR-Cas9,
which will be discussed later in more detail, is prohibited
for various safety reasons. However, the rate of application
of CRISPR-Cas9 to somatic cells is gradually increasing
in order to transfer the desired characteristics to our
lives. Many phenotypic characteristics have a genetic
component independent of the environment. By utilizing
this feature, CRISPR-Cas9 can be used to improve the
performance of athletes, to prevent violent behavior,
or to reduce dependence (Rodriguez, 2016). Although
gene therapy is often used to treat patients for their own
benefit, the criminal justice system may require repeater or
dangerous offenders to correct the genes associated with
violence by genome editing technologies in the future.
One of the biggest dilemmas here is to obtain informed
consent for an underage person if the intervention is
made during the development of the zygote. This will give
parents or guardians the right to make decisions on behalf
of minors for nonhealth reasons. Furthermore, when
socially assessed, some genetically improved populations
or individuals may have some advantages in comparison
to others in terms of various features such as mental and
physical capacity (Brokowski, 2018). Therefore, the use of
CRISPR-Cas9 in genome enhancement should be seriously
discussed both socially and morally.
4.4. Military research
The use of CRISPR technology for military purposes is
generally considered within the scope of nontherapeutic
enhancement and is covered similarly. From this point of
view, related bioethical issues are commonly discussed
in terms of concepts of benefit/risk, informed consent,
and accessibility (Greene and Master, 2018). A notable
bioethical problem is the off-target mutations that have
been mentioned in relation to other topics. Off-target
mutations can cause many undesirable changes in the
genome or even lead to fatal diseases. Current information
obtained from studies on off-target mutations caused by
CRISPR on the genome is very limited. Therefore, the
benefit/risk relationship needs to be evaluated carefully.
In addition, the possibility that this technology can be
used for the production of new biological weapons is
frightening.
Another ambiguous issue that needs to be discussed in
military enhancement applications is informed consent.
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It could be difficult to obtain informed consent forms
independently without any interaction among individuals
due to military training methods, strict norms, and
chains of command. Additionally, some soldiers may have
difficulty in understanding the concepts of gene therapy
and genome editing, as well as the potential risks and
benefits of the applications (Greene and Master, 2018).
One important ethical issue is that the use of such
technologies will support ongoing inequalities among
military parties (Amoroso and Wenger, 2003). CRISPR
is currently an expensive technology. Some developed
countries might think of using this technology to further
strengthen their defenses and even attack underdeveloped
or developing countries. This situation could cause
a constant tension, making it difficult to provide an
environment of peace and stability worldwide.
4.5. Generation of chimeric animals for organ
transplantation
Organ transplantation is the replacement of an organ that
cannot function in an individual’s body with a healthy
organ from a living donor or cadaver. The primary purpose
is to save the life of the patient, who is in danger of organ
failure, and to increase the lifespan and quality of life
(Black et al., 2018). The development of chimeric animals
may prevent patients from spending precious time waiting
for an appropriate donor.
Bioethical issues in the generation of chimeric animals
arise from the fact that chimeras contain human nerve and
germ cells (Polcz and Lewis, 2016). The two main issues
can be summarized as defining the order of nature and
the moral disorders caused by how the organism is treated
depending on whether the organism is accepted as human
or animal. Some people think that chimeric embryos will
affect human dignity and identity because they have the
power to develop organisms with human-derived cells and
tissues. The others state that chimeric organisms containing
human cells cannot turn into humans and therefore will
not affect human dignity. They also argue that the humanlike features imparted to chimeras will neither affect the
biological environment nor the moral status of animals
and will never reach human consciousness (Koplin, 2019;
Degrazia, 2019).
4.6. Animal welfare and dignity
Animal welfare is another bioethical concern encountered
during the application of genome editing technologies on
animals. First of all, the possibility of off-target mutations
in the genome can lead to diseases or different side effects
in animals (Ishii, 2017a; Schultz-Bergin, 2018; de Graeff
et al., 2019). Such a situation will adversely affect animal
welfare (Rodriguez, 2017).
The second bioethical issue to be discussed could be the
concerns about “animal dignity” (Eriksson et al., 2018) and
alterations in their natural environments and physiological
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needs (Manesh et al., 2014). Some studies have stated that
the use of animals as objects only serving for humans
is not ethically or morally acceptable (Martinelli et al.,
2014; Fung and Kerridge, 2016; Greenfield, 2017), and
such practices can lead to greater control over humans on
animals (Ishii, 2017a; de Graeff et al., 2019). Some others
think that animals are not bound by any moral law and
therefore there is no need for a discussion regarding animal
dignity (Heeger, 2015; Shriver and McConnachie, 2018).
Schultz-Bergin (2017) stated that animal rights, welfare,
and dignity will not be adversely affected since these
animals will occur through genome editing technologies.
The existence of contrary opinions on this matter indicates
that the mentioned bioethical issues will be on the agenda
for a long time.
4.7. CRISPR-Cas9 for human germline
The potential for using CRISPR-Cas9 for genome editing
in the human germline has raised serious ethical debates.
Until 2015, all therapeutic applications in humans
were performed in somatic cells using genome editing
technologies. However, in 2015, the editing of the human
germline performed by Chinese scientist Huang and
his team with CRISPR-Cas9 raised new social, moral,
and bioethical issues (Liang et al., 2015; Ormond et al.,
2017). Bioethical issues caused by genome editing in the
germline can be classified into two main topics depending
on the success and failure of genome editing technologies
(Ormond et al., 2017; Greely, 2019).
4.7.1. Issues that may occur in the failure of germline
genome editing
Some of the ethical dilemmas of genome editing in the
germline arise from the fact that changes in the genome can
be transferred to the next generations. Therapeutic genome
editing in somatic cells generally does not cause significant
concerns when assessing the risk/benefit balance and the
use of informed consent. The application of CRISPR-Cas9
in the germline is considered more problematic because
of the risk of causing various mutations and side effects
and transferring undesirable changes to future generations
(Cyranoski and Reardon, 2015; Brokowski, 2018; Cai et al.,
2018; Halpern et al., 2019). In fact, Huang and his team
found that nontarget mutations in the genome occurred
and the study was terminated earlier than planned (Liang
et al., 2015). Nontarget mutations are unintentional
mutations in the genome and may have harmful effects
on the organism as these mutations can lead to cell death
or transformation (Zhang et al., 2014). Frighteningly,
researchers have found that mutations caused by CRISPRCas9 in embryos are much more common than in mouse
or human adult cells (Cyranoski and Reardon, 2015). In a
study performed with human embryos, it was stated that
nontarget mutations occur only in the exon regions and
therefore the number of mutations may be much higher

than expected (Liang et al., 2015). Due to the high risk of
nontarget mutations, some scientists argue that genome
editing studies in germline cells should be terminated and
its future should be discussed (Cyranoski and Reardon,
2015). Some scientists state that newly developed CRISPRCas9 could reduce or even prevent the number of nontarget
mutations. In this method, the efficiency of CRISPR-Cas9
was increased by using Cas9-regulated human iPSCs in
region-specific gene targeting (Yumlu et al., 2019).
Another bioethical dilemma is the cost of germline
genome editing. Genome editing is an expensive
technology (Wilson and Carroll, 2019). While families
in rich countries may have the power to cover this cost,
families in developing countries may not. This situation
may cause children born in developed countries to have an
unfair advantage in terms of various characteristics such
as intelligence and physical state compared to children in
other countries (Otieno, 2015).
CRISPR-Cas9 is based on the use of nuclease enzymes.
The nuclease enzymes used may not be as effective as
desired and not be able to cut all copies of the target gene,
or the cell may begin to divide before genome editing is
completed. As a result, a condition called genetic mosaicism
can occur (Lanphier et al., 2015). Genetic mosaicism is the
presence of genetically different somatic cell populations
in an organism and is often masked. Mosaicism can also
lead to major phenotypic changes, the formation of fatal
genetic mutations (Capalbo and Rienzi, 2017), and some
genetic diseases such as Down, Klinefelter, and Turner
Syndromes (Otieno, 2015). Therefore, the nuclease
cleavage sites should be exactly confirmed and the
possibility of mosaicism should be completely eliminated.
One of the important bioethical issues is side effects
in embryos. It is pointed out that the possible side effects
cannot be predicted before birth and the consequences
are not clearly known (Otieno, 2015; Brokowski, 2018).
Controls can only be performed in a small group of cells.
This limitation causes the effects of genome editing on
embryos to be unknown and unprevented until birth.
In fact, it should be considered that it may take years for
many potential problems to emerge (Lanphier et al., 2015;
Halpern et al., 2019).
4.7.2. Issues that may occur in the successful application
of germline genome editing
The first of the bioethical issues of successful germline
genome editing is the use for nontherapeutic changes
(Lanphier et al., 2015; Greely, 2019). Such uses will lead
to new questions about breeding (eugenics) of the human
species and its position in the universe (Yang, 2015). In
one study, the fur color of rats was successfully changed by
genome editing (Yoshimi et al., 2014). It is possible that the
skin color of people could be changed in the future. Since
the characteristics of individuals can be determined by
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genome editing rather than blood relations, the possibility
that children with similar physical and mental health can
be born in the same way should be considered (Ishi, 2015).
The second bioethical issue is what the fate of
children born using genome editing will be. From whom
or where informed consent will be obtained in the
case of undesirable effects on behalf of genome-edited
children and whether informed consent will give detailed
information are important questions (Beriain and del
Cano, 2018; Neuhaus and Zacharias, 2018; Sykora, 2018;
Knoppers and Kleiderman, 2019). While clear informed
consent can be given for genome-edited somatic cells to be
used in clinical trials, it is an enigma to whom and how to
give precise information about the potential risks involved
in germline editing (Lanphier et al., 2015; Neuhaus and
Zacharias, 2018; Knoppers and Kleiderman, 2019).
In December 2015, the International Summit on
Human Gene Editing was convened to discuss the
social, moral, and bioethical issues caused by genome
editing in the human germline. The results of the summit
concluded that basic and clinical investigations should
be continued in accordance with the appropriate legal
and ethical regulations; however, genome editing on
gametocytes and embryos that would cause hereditary
changes in humans was found to be irresponsible. It was
therefore emphasized that the use of CRISPR-Cas9 on the
human germline should be postponed until a solution is
found for existing bioethical, social, legal, and technical
concerns and issues (Baltimore et al., 2015). In addition,
it was agreed to establish an international forum where
such concerns could be addressed continuously and the
studies in different countries could be organized together
(Baltimore et al., 2015; Lanphier et al., 2015; Olson,
2015). The NIH announced that genome editing studies
in human embryos will not be financially supported
(Collins, 2015). In spite of the joint decisions that were
made, in February 2016, British scientists were allowed
to use CRISPR-Cas9 and similar technologies in human
embryos for research purposes only (https://www.bbc.
com/news/health-35459054). In March 2017, the US
National Academy of Sciences and the American Society
of Human Genetics published a position statement stating
that they should be aware of the scientific and bioethical
issues that can be caused by germline genome editing, but,
on the other hand, research should continue (Ormond et
al., 2017). As of January 2020, 24 countries have forbidden
genome editing in human embryos by law and 9 countries
have banned it by guidelines. However, there are countries
that do not impose strict prohibitions on germline genome
editing (Ishii, 2017b; Lau et al., 2018; Macintosh, 2019).
5. Discussion and future directions
Thanks to its high accuracy, ease of use, and relatively low
cost, CRISPR-Cas9 offers a wide range of applications for
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many people in the medical, agricultural, livestock, and
environmental sectors. Furthermore, its precision and
accuracy are much higher compared to older technologies
such as ZFN and TALEN (Mittal, 2019). The powerful
effects of CRISPR-Cas9 have raised many social, moral,
and bioethical issues.
Discussions have generally focused on the social,
bioethical, and legal consequences of using genome editing
technology in human germline cells. Scientists generally
agree that CRISPR-Cas9 should be allowed for use in the
creation of human disease models, and in understanding
the development and molecular mechanisms of diseases;
however, it should be prohibited for the purposes of
eugenics or enhancement. When ethical issues, safety
concerns, and application difficulties are considered
together, it is predicted that therapeutic genome editing
in human embryos will not be possible in the near future.
Thus, the risk of hereditary nontarget genetic mutation is
higher than the possible treatment benefits and it affects the
principle of intentional harm. Nevertheless, it is clear that
scientists will apply CRISPR-Cas9 in germline cells in the
future if solutions are found to the issues mentioned here
(Duardo-Sánchez, 2017; Hirsch et al., 2019). CRISPR-Cas9
must be fully reliable for therapeutic use in germline cells.
Social, legal, and bioethical issues should be discussed in
detail once genome editing technologies have reached the
permissible level of safety for clinical applications in the
prevention of genetic diseases (Rossant, 2018; Cathomen
et al., 2019). Subsequently, regulatory laws that may
eliminate breaches of germline genome editing will need
to be reassessed (Rodriguez, 2016; Duardo-Sánchez, 2017;
Cathomen et al., 2019; Macintosh, 2019). The therapeutic
use of CRISPR-Cas9 and its rapid rise in the medical
field are expected to continue. While studies on the use
of CRISPR-Cas9 for clinical purposes are continuing, the
necessary legal, social, and ethical legislation should be put
into practice as soon as possible and the public conscience
should not be ignored.
On the other hand, the potential effects of CRISPRCas9 in other areas should not be forgotten. CRISPRCas9 is not just about social and bioethical issues related
to people. Interactions with other organisms and the
environment, such as the consideration of the principle
of intentional harm in risk assessment, safety measures to
prevent ecological degradation, or potential use in genetic
enhancement of animals and agriculture products should
also be discussed (Rodriguez, 2016; Hirsch et al., 2019).
There are serious concerns about changes in the natural
ecosystem that may occur if the GMOs produced with
CRISPR-Cas9 are released to the ecosystem in a controlled
or uncontrolled manner. Considering the applications
of CRISPR-Cas9 that protect mosquitoes from malaria
parasites (Gantz et al., 2015) or make female mosquitoes
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infertile (Hammond et al., 2016), the effect of GM
mosquitoes on other organisms with which they are
associated in their ecosystems cannot be predicted. It is
clear that small-scale research in the laboratory does not
fully reflect possible changes in the natural ecosystem
(Carroll, 2017). In agriculture, another concern about
GMOs produced with CRISPR-Cas9 is whether they will
be accepted by the public. GMOs that were produced
using different technologies in the past faced harsh
public reactions (Carroll, 2017). Furthermore, the fact
that GMOs produced with CRISPR-Cas9 are difficult
to identify outside the laboratory raises safety concerns
(Shinwari et al., 2017). Before the launch of such products,
the necessary explanations and declarations should be
made by the authorities in a transparent and clear manner
in order to prevent misjudgments and questions that may
occur in the public, and precautions and arrangements
should be established to ensure the safety of the public.
Another issue to consider about CRISPR-Cas9 is
patenting. Patenting can considerably limit the application
of such technologies. Unilateral patenting can significantly
increase the profitability of biotechnology companies,
which may lead to a rise of bioethical issues. There is
disagreement in the scientific community regarding the
patenting or nonpatenting of GMOs to be used specifically
for therapeutic purposes (Shinwari et al., 2017; Sherkow,
2018). However, there are some who think that patenting
will help to eliminate and regulate the deficiencies in the

field (Rodriguez, 2016; Shinwari et al., 2017). It should
not be forgotten that the most important of these debates
about patenting is commercialization and the release of
only reliable products.
In recent years, deals between the scientific community
and the pharmaceutical and biotechnology sectors for
the therapeutic use of CRISPR-Cas9 have raised public
safety concerns (Shinwari et al., 2017; Carroll, 2019) The
guidelines and legislations that will regulate the content
and application of these deals should be prepared as
quickly as possible and shared with the public. Due to
the challenges and bioethical issues of CRISPR-Cas9,
the scientific community and other interested bioethical,
social, legal, and governmental parties should be provided
with a detailed guide for future processing and use of
this technology (Otieno, 2015; Shinwari et al., 2017;
Cathomen et al., 2019). In this way, a long-term policy can
be developed that will support the scientific development
of CRISPR-Cas9 technology together with the discussion
of the possible problems in advance and preparation of
solution plans.
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